Why the study?
Adiponectin has been linked to carotid intima medial thickness mainly in high-risk populations, prompting evaluation of this association in Indian subjects without diabetes or cardiovascular disease.
Does serum adiponectin correlate with carotid intima medial thickness and visceral body fat in non-diabetic patients aged 30-60 years?
Does serum adiponectin correlate with carotid intima medial thickness and visceral body fat in non-diabetic patients aged 30-60 years?
Lower serum adiponectin levels are significantly associated with increased carotid intima medial thickness in non-diabetic individuals, suggesting its potential utility as an early biomarker for subclinical atherosclerosis.
Supports adiponectin as possible early atherosclerosis marker; leaves open causality and utility pending prospective data.
Introduction: Cardiovascular disease is the leading cause of disability adjusted life years in developed and developing countries. Traditional cardiovascular risk factors such as obesity, hypertension and disturbances of glucose and lipid metabolism are commonly clustered and insulin resistance has been considered a relevant pathophysiological link. However, a number of cardiovascular events occur in absence of these risk factors indicating that there might be a substantial need for identification of these novel factors. Adipose tissue secretes adiponectin which participates in energy homeostasis and enhances insulin sensitivity. An inverse association of adiponectinemia with obesity, insulin resistance, inflammation, type 2 diabetes and atherosclerosis has been reported. Adiponectin has been associated with carotid intima medial thickness(CIMT), mainly in high cardiovascular risk population Therefore, we performed this study to assess the association of adiponectin with CIMT in Indian subjects without diabetes or cardiovascular disease Material and Method: We conducted a cross sectional observational study at Safdarjung hospital. Results: Our study proved that adiponectin can be used as marker of subclinical atherosclerosis in non diabetic patients. There is an inverse correlation of serum adiponectin with CIMT (p <0.001). However, we did not observe any correlation between serum adiponectin with visceral body fat and BMI. Summary: Hence, we can say that as the level of serum adiponectin decreases CIMT increases and vice versa. Therefore serum adiponectin can be used as the marker of subclinical atherosclerosis.
No takes yet. Share an insight, caveat, or question.
Dr Jyoti Verma (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: